119 related articles for article (PubMed ID: 2151235)
1. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
2. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
3. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
Berni R; Formelli F
FEBS Lett; 1992 Aug; 308(1):43-5. PubMed ID: 1386578
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
6. Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).
Smith JE; Lawless DC; Green MH; Moon RC
J Nutr; 1992 Oct; 122(10):1999-2009. PubMed ID: 1388202
[TBL] [Abstract][Full Text] [Related]
7. Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin.
Malpeli G; Folli C; Berni R
Biochim Biophys Acta; 1996 May; 1294(1):48-54. PubMed ID: 8639713
[TBL] [Abstract][Full Text] [Related]
8. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
9. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
[TBL] [Abstract][Full Text] [Related]
10. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
11. The synthetic retinoid fenretinide does not affect circulating hormone concentrations.
Secreto G; Costa A; Recchiane C; Pizzichetta M; Ballerini P
Breast Cancer Res Treat; 1988 Dec; 12(3):315-6. PubMed ID: 2976280
[No Abstract] [Full Text] [Related]
12. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.
Schaffer EM; Ritter SJ; Smith JE
J Nutr; 1993 Sep; 123(9):1497-503. PubMed ID: 8360775
[TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors.
Sani BP; Shealy YF; Hill DL
Carcinogenesis; 1995 Oct; 16(10):2531-4. PubMed ID: 7586162
[TBL] [Abstract][Full Text] [Related]
14. HINT predictive analysis of binding between retinol binding protein and hydrophobic ligands.
Marabotti A; Balestreri L; Cozzini P; Mozzarelli A; Kellogg GE; Abraham DJ
Bioorg Med Chem Lett; 2000 Sep; 10(18):2129-32. PubMed ID: 10999486
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Peng YM; Dalton WS; Alberts DS; Xu MJ; Lim H; Meyskens FL
Int J Cancer; 1989 Jan; 43(1):22-6. PubMed ID: 2521335
[TBL] [Abstract][Full Text] [Related]
16. The interaction of N-ethyl retinamide with plasma retinol-binding protein (RBP) and the crystal structure of the retinoid-RBP complex at 1.9-A resolution.
Zanotti G; Malpeli G; Berni R
J Biol Chem; 1993 Nov; 268(33):24873-9. PubMed ID: 8227049
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
18. Vitamin A transport complex during treatment with an oral aromatic retinoid (RO 10-9359).
Lauharanta J
Acta Derm Venereol; 1981; 61(3):264-7. PubMed ID: 6167115
[TBL] [Abstract][Full Text] [Related]
19. Crystallographic studies on complexes between retinoids and plasma retinol-binding protein.
Zanotti G; Marcello M; Malpeli G; Folli C; Sartori G; Berni R
J Biol Chem; 1994 Nov; 269(47):29613-20. PubMed ID: 7961949
[TBL] [Abstract][Full Text] [Related]
20. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
